Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design

Eur J Med Chem. 2014 Oct 6:85:1-15. doi: 10.1016/j.ejmech.2014.07.081. Epub 2014 Jul 24.

Abstract

We have discovered a series of triazole/oxazole-containing 2-substituted 2-aminopropane-1,3-diol derivatives as potent and selective S1P1 agonists (prodrugs) based on pharmacophore-guided rational design. Most compounds showed high affinity and selectivity for S1P1 receptor. Compounds 19b, 19d and 19p displayed clear dose responsiveness in the lymphocyte reduction model when administered orally at doses of 0.3, 1.0, 3.0 mg/kg with reduced effect on heart rate. These three compounds were also identified to have favorable pharmacokinetic properties.

Keywords: Immunomodulator; Lymphocyte; Pharmacophore; Prodrug; S1P(1) agonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CHO Cells
  • Cricetinae
  • Cricetulus
  • Drug Design*
  • Heart Rate / drug effects
  • Lymphocytes / drug effects
  • Male
  • Models, Molecular
  • Molecular Conformation
  • Oxazoles / chemistry*
  • Oxazoles / pharmacokinetics
  • Oxazoles / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Lysosphingolipid / agonists*
  • Receptors, Lysosphingolipid / chemistry
  • Structure-Activity Relationship
  • Triazoles / chemistry*
  • Triazoles / pharmacokinetics
  • Triazoles / pharmacology*

Substances

  • Oxazoles
  • Receptors, Lysosphingolipid
  • Triazoles